PL2694067T3 - Pochodne pirydopirazyny i ich zastosowanie - Google Patents

Pochodne pirydopirazyny i ich zastosowanie

Info

Publication number: PL2694067T3
Authority: PL; Poland
Prior art keywords: pyridopyrazine derivatives; pyridopyrazine; derivatives
Prior art date: 2011-04-06

Application number

PL12713705T

Other languages

English (en)

Inventor

Matthias Gerlach

Irene Seipelt

Lars Blumenstein

Gilbert Mueller

Eckhard Günther

Tilmann Schuster

Michael Teifel

Original Assignee

Aeterna Zentaris Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-06

Filing date

2012-04-04

Publication date

2016-01-29

2012-04-04 Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh

2016-01-29 Publication of PL2694067T3 publication Critical patent/PL2694067T3/pl

Links

YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical class N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Virology (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Child & Adolescent Psychology (AREA)

PL12713705T 2011-04-06 2012-04-04 Pochodne pirydopirazyny i ich zastosowanie PL2694067T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201161472245P	2011-04-06	2011-04-06
EP11161248A EP2508184A1 (en)	2011-04-06	2011-04-06	Pyridopyrazine derivatives and their use
EP12713705.7A EP2694067B1 (en)	2011-04-06	2012-04-04	Pyridopyrazine derivatives and their use
PCT/EP2012/056138 WO2012136691A1 (en)	2011-04-06	2012-04-04	Pyridopyrazine derivatives and their use

Publications (1)

Publication Number	Publication Date
PL2694067T3 true PL2694067T3 (pl)	2016-01-29

Family

ID=44350566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12713705T PL2694067T3 (pl)	2011-04-06	2012-04-04	Pochodne pirydopirazyny i ich zastosowanie

Country Status (20)

Country	Link
US (2)	US8791118B2 (pl)
EP (3)	EP2508184A1 (pl)
JP (2)	JP5963844B2 (pl)
KR (2)	KR20140025442A (pl)
CN (2)	CN103501788A (pl)
AR (2)	AR085843A1 (pl)
AU (2)	AU2012238681A1 (pl)
BR (1)	BR112013025630A2 (pl)
CA (2)	CA2832337A1 (pl)
ES (1)	ES2552515T3 (pl)
IL (2)	IL228436A0 (pl)
MX (2)	MX2013011444A (pl)
NZ (1)	NZ615578A (pl)
PH (1)	PH12013501904A1 (pl)
PL (1)	PL2694067T3 (pl)
RU (2)	RU2013146618A (pl)
SG (2)	SG193978A1 (pl)
TW (2)	TW201302742A (pl)
WO (2)	WO2012136691A1 (pl)
ZA (2)	ZA201306862B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017033113A1 (en)	2015-08-21	2017-03-02	Acerta Pharma B.V.	Therapeutic combinations of a mek inhibitor and a btk inhibitor
US20170168056A1 (en) *	2015-11-13	2017-06-15	Massachusetts Institute Of Technology	Methods and compositions for detecting and modulating cancer cells
SG11201804901WA (en)	2015-12-22	2018-07-30	SHY Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
WO2017180817A1 (en) *	2016-04-15	2017-10-19	Musc Foundation For Research Development	Treatment of septicemia and ards with erk inhibitors
EA201992780A1 (ru)	2017-06-21	2020-06-02	ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи	Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US20200138921A1 (en) *	2017-06-23	2020-05-07	The Trustees Of Columbia University In The City Of New York	Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
EP3806833A1 (en)	2018-06-15	2021-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
US12391705B2 (en)	2018-12-19	2025-08-19	Shy Therapeutics, Llc	Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN112830897B (zh) *	2019-11-22	2022-09-09	石家庄以岭药业股份有限公司	含脲基苯并咪唑类衍生物及其制备方法和应用
US20240109883A1 (en)	2020-12-31	2024-04-04	Evrys Bio, Llc	Anti-Tumor Compositions and Methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3809695A (en)	1967-04-19	1974-05-07	Degussa	2,6-dichloro-3-nitro-pyridine
DE69600385T2 (de)	1995-03-28	1998-12-17	Sumitomo Chemical Co., Ltd., Osaka	Verfahren zur Herstellung von Aminonitropyridinen
UA71555C2 (en)	1997-10-06	2004-12-15	Zentaris Gmbh	Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
ATE529109T1 (de)	1997-12-22	2011-11-15	Bayer Healthcare Llc	Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
CN101851173A (zh)	2001-09-14	2010-10-06	梅特希尔基因公司	组蛋白脱乙酰化酶抑制剂
US20040023961A1 (en)	2002-02-11	2004-02-05	Bayer Corporation	Aryl ureas with raf kinase and angiogenisis inhibiting activity
US7223738B2 (en)	2002-04-08	2007-05-29	Merck & Co., Inc.	Inhibitors of Akt activity
EP1496981A2 (en)	2002-04-08	2005-01-19	Merck & Co., Inc.	Method of treating cancer
EP1496906A4 (en)	2002-04-08	2006-05-03	Merck & Co Inc	HEMMER OF ACT ACTIVITY
US7718651B2 (en)	2002-07-02	2010-05-18	Southern Research Institute	Inhibitors of FtsZ and uses thereof
DE10323345A1 (de)	2003-05-23	2004-12-16	Zentaris Gmbh	Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
PT1636228E (pt) *	2003-05-23	2009-02-02	Aeterna Zentaris Gmbh	Novas piridopirazinas e sua utilização como moduladores de cinases
WO2005007099A2 (en)	2003-07-10	2005-01-27	Imclone Systems Incorporated	Pkb inhibitors as anti-tumor agents
US7592340B2 (en)	2003-12-04	2009-09-22	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
GB0413953D0 (en)	2004-06-22	2004-07-28	Syngenta Participations Ag	Chemical compounds
EP1790342A1 (de)	2005-11-11	2007-05-30	Zentaris GmbH	Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
WO2007054556A1 (de)	2005-11-11	2007-05-18	Æterna Zentaris Gmbh	Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
US8217042B2 (en)	2005-11-11	2012-07-10	Zentaris Gmbh	Pyridopyrazines and their use as modulators of kinases
EP1785423A1 (de) *	2005-11-11	2007-05-16	Zentaris GmbH	Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen
US7733554B2 (en) *	2006-03-08	2010-06-08	E Ink Corporation	Electro-optic displays, and materials and methods for production thereof
KR101097177B1 (ko)	2006-07-06	2011-12-22	한국화학연구원	2-알킬레닐옥시-3-에티닐피리도［2,3-ｂ］피라진 유도체
GB0614471D0 (en)	2006-07-20	2006-08-30	Syngenta Ltd	Herbicidal Compounds
US20100093738A1 (en)	2006-10-06	2010-04-15	Basf Se	Fungicidal Compounds and Fungicidal Compositions
EP1990342A1 (en)	2007-05-10	2008-11-12	AEterna Zentaris GmbH	Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
MX2010005960A (es) *	2007-11-30	2010-06-11	Schering Corp	Biomarcadores de braf.
NZ586418A (en)	2007-12-19	2012-09-28	Cancer Rec Tech Ltd	Pyrido[2,3-b]pyrazine-8-substituted compounds and their use

2011
- 2011-04-06 EP EP11161248A patent/EP2508184A1/en not_active Withdrawn
2012
- 2012-04-03 TW TW101111888A patent/TW201302742A/zh unknown
- 2012-04-03 TW TW101111889A patent/TWI564299B/zh not_active IP Right Cessation
- 2012-04-04 PH PH1/2013/501904A patent/PH12013501904A1/en unknown
- 2012-04-04 MX MX2013011444A patent/MX2013011444A/es unknown
- 2012-04-04 WO PCT/EP2012/056138 patent/WO2012136691A1/en not_active Ceased
- 2012-04-04 CA CA2832337A patent/CA2832337A1/en not_active Abandoned
- 2012-04-04 AU AU2012238681A patent/AU2012238681A1/en not_active Abandoned
- 2012-04-04 CN CN201280022158.8A patent/CN103501788A/zh active Pending
- 2012-04-04 SG SG2013072624A patent/SG193978A1/en unknown
- 2012-04-04 CN CN201280019613.9A patent/CN103826636A/zh active Pending
- 2012-04-04 US US13/439,150 patent/US8791118B2/en not_active Expired - Fee Related
- 2012-04-04 AR ARP120101162A patent/AR085843A1/es unknown
- 2012-04-04 BR BR112013025630A patent/BR112013025630A2/pt not_active IP Right Cessation
- 2012-04-04 EP EP12713705.7A patent/EP2694067B1/en active Active
- 2012-04-04 SG SG2013074430A patent/SG194097A1/en unknown
- 2012-04-04 US US13/439,107 patent/US8912189B2/en not_active Expired - Fee Related
- 2012-04-04 RU RU2013146618/04A patent/RU2013146618A/ru not_active Application Discontinuation
- 2012-04-04 WO PCT/EP2012/056142 patent/WO2012136694A1/en not_active Ceased
- 2012-04-04 PL PL12713705T patent/PL2694067T3/pl unknown
- 2012-04-04 MX MX2013011490A patent/MX2013011490A/es unknown
- 2012-04-04 AU AU2012238678A patent/AU2012238678B2/en not_active Ceased
- 2012-04-04 NZ NZ615578A patent/NZ615578A/en not_active IP Right Cessation
- 2012-04-04 KR KR1020137029385A patent/KR20140025442A/ko not_active Withdrawn
- 2012-04-04 CA CA2832321A patent/CA2832321A1/en not_active Abandoned
- 2012-04-04 JP JP2014503125A patent/JP5963844B2/ja not_active Expired - Fee Related
- 2012-04-04 EP EP12713706.5A patent/EP2694068A1/en not_active Withdrawn
- 2012-04-04 RU RU2013146619/15A patent/RU2013146619A/ru not_active Application Discontinuation
- 2012-04-04 JP JP2014503127A patent/JP2014510125A/ja active Pending
- 2012-04-04 AR ARP120101163A patent/AR085844A1/es unknown
- 2012-04-04 ES ES12713705.7T patent/ES2552515T3/es active Active
- 2012-04-04 KR KR1020137029386A patent/KR20140025443A/ko not_active Withdrawn
2013
- 2013-09-12 ZA ZA2013/06862A patent/ZA201306862B/en unknown
- 2013-09-12 ZA ZA2013/06864A patent/ZA201306864B/en unknown
- 2013-09-15 IL IL228436A patent/IL228436A0/en unknown
- 2013-09-15 IL IL228433A patent/IL228433A0/en unknown

Also Published As

Publication number	Publication date
RU2013146619A (ru)	2015-05-20
CA2832337A1 (en)	2012-10-11
WO2012136694A1 (en)	2012-10-11
AU2012238681A1 (en)	2013-10-03
JP5963844B2 (ja)	2016-08-03
CA2832321A1 (en)	2012-10-11
IL228433A0 (en)	2013-12-31
JP2014510125A (ja)	2014-04-24
EP2694067A1 (en)	2014-02-12
SG193978A1 (en)	2013-11-29
TWI564299B (zh)	2017-01-01
KR20140025443A (ko)	2014-03-04
ZA201306864B (en)	2014-11-26
EP2694068A1 (en)	2014-02-12
AR085843A1 (es)	2013-10-30
US8791118B2 (en)	2014-07-29
PH12013501904A1 (en)	2015-04-22
AU2012238678A1 (en)	2013-10-03
RU2013146618A (ru)	2015-05-20
AR085844A1 (es)	2013-10-30
TW201302743A (zh)	2013-01-16
BR112013025630A2 (pt)	2016-12-27
WO2012136691A1 (en)	2012-10-11
JP2014510124A (ja)	2014-04-24
CN103501788A (zh)	2014-01-08
ES2552515T3 (es)	2015-11-30
US8912189B2 (en)	2014-12-16
IL228436A0 (en)	2013-12-31
EP2508184A1 (en)	2012-10-10
US20120259151A1 (en)	2012-10-11
SG194097A1 (en)	2013-11-29
NZ615578A (en)	2015-08-28
EP2694067B1 (en)	2015-08-26
ZA201306862B (en)	2014-06-25
AU2012238678B2 (en)	2016-11-17
MX2013011444A (es)	2013-10-17
KR20140025442A (ko)	2014-03-04
TW201302742A (zh)	2013-01-16
US20120258080A1 (en)	2012-10-11
MX2013011490A (es)	2013-11-04
CN103826636A (zh)	2014-05-28

Publication	Publication Date	Title
AP4055A (en)	2017-03-07	Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
IL233051B (en)	2019-02-28	Anti-phf-tau antibodies and uses thereof
IL230511A0 (en)	2014-03-31	4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
EP2828258A4 (en)	2015-08-12	NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
IL230917A (en)	2017-02-28	1dyrk inhibitors and their uses
IL229844B (en)	2022-02-01	Anti-psgl-1 antibodies and their use
GB201111705D0 (en)	2011-08-24	Compounds and their use
IL228433A0 (en)	2013-12-31	Pyridopyrazine history and their use
GB201110783D0 (en)	2011-08-10	Methods and uses
IL231082A0 (en)	2014-03-31	Pyrimido-pyridazinone compounds and their use
GB201116774D0 (en)	2011-11-09	Uses and methods
EP2716359A4 (en)	2014-04-23	COMPLEX AND USES THEREOF
EP2668044A4 (en)	2015-11-25	COMPOSITIONS AND THEIR USE
GB201114448D0 (en)	2011-10-05	Compounds and their use
GB201108490D0 (en)	2011-07-06	Methods and uses
IL232809A0 (en)	2014-08-03	Carboxamides converted at position 2 in isothiazolopyridine and their use as medicinal preparations
GB201104444D0 (en)	2011-04-27	Compounds and their use
GB201112578D0 (en)	2011-08-31	Pharmaceutical preparation and use
GB201119443D0 (en)	2011-12-21	GoWinging Concept and patent
PT2734522T (pt)	2019-02-04	4-imidazopiridazina-1-il-benzamidas e 4-imidazotriazin-1- il-benzamidas como inibidores de btk
GB201107656D0 (en)	2011-06-22	Short back and sides